Takeda's Response to COVID-19 If you were diagnosed with COVID-19 and have recovered, you may be able to help in furthering research into a potential therapy for others by donating your plasma.

Takeda's Commitment

MENU
Commitment to Integrity, Transparency and Diversity
Clinical Trial Registration
Clinical Trial Results Disclosure
Sharing of Clinical Trial Results with Participants
Clinical Trial Results Publication
Data Sharing with Researchers
Takeda Policies
MENU
Commitment to Integrity, Transparency and Diversity
Clinical Trial Registration
Clinical Trial Results Disclosure
Sharing of Clinical Trial Results with Participants
Clinical Trial Results Publication
Data Sharing with Researchers
Takeda Policies
PREVIOUS

Commitment to Integrity, Transparency and Diversity

The Nori. Written in 1940 by Chobei Takeda V, the Nori (shown here) is a list of 5 principles that guide all Takeda employees’ actions. The Nori principles are now referred to as Takeda-ism.

For more than 230 years, the Takeda brand has embodied the values of fairness, honesty, and most importantly, integrity. Known as “Takeda-ism,” these core values serve as guiding principles in our pursuit to promote better health and brighter futures for our patients through innovative medicines.

Today, Takeda continues our tradition of integrity by prioritizing clinical research transparency and making clinical research information and results available to the public.

“Greater transparency and responsible data sharing during development of new medicines and throughout their life cycles are core topics for the pharmaceutical industry. At Takeda, we recognize that responsible sharing of clinical trial data with patients, healthcare providers, researchers, and the public is critical to delivering innovative medicines. Increased transparency improves public trust in our products and treatments and helps all our stakeholders make better healthcare decisions.”

Jeremy G Chadwick, Ph.D., Head of Global Development Office, Takeda R&D

Takeda is committed to compliance with clinical trial transparency laws and regulations as well as an objective, unbiased clinical trial results reporting, regardless of outcome. This includes a broader sharing of clinical trial data in ways that safeguard patient privacy, respect regulatory processes and oversight, and maintain incentives to invest in biomedical research.

Our policies meet or exceed the pharmaceutical industry’s guidelines and best practices relating to clinical trial registration and results disclosure, including guidelines issued by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA); the European Federation of Pharmaceutical Industries and Associations (EFPIA); the Japan Pharmaceutical Manufacturers Association (JPMA); and the Pharmaceutical Research and Manufacturers of America (PhRMA).

Takeda adheres to and seeks to exceed requirements laid out by the Principles for Responsible Clinical Trial Data Sharing, which were issued by the EFPIA and PhRMA in July 2013. Takeda will do this by:

Diversity in clinical trial participation leads to better research, treatment and health outcomes for individuals from a diverse range of backgrounds according, but not limited to age, gender, race and ethnicity. Because some groups have been underrepresented in clinical research in the past, there is an urgent need to ensure appropriate representation in clinical trials and to gain information about treatment outcomes in diverse populations. This is particularly important for clinical trials studying diseases that disproportionately affect specific ethnic minorities.

Takeda is therefore focused on enhancing the diversity of clinical trial populations and promoting participants’ enrollment practices to provide clinical trial results that better reflect the populations most likely to use medical products once they are approved. Takeda is establishing concrete policies and practices to address diversity in clinical trials, as outlined in the PhRMA Principles on the Conduct of Clinical Trials.

NEXT